BioCryst Pharmaceuticals (BCRX) said Wednesday that the first participant has been enrolled in a phase 1 trial evaluating BCX17725 to treat patients with Netherton syndrome, a rare, lifelong genetic disorder affecting the skin, hair and immune system.
The trial will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of the drug candidate.
The company said it expects to report initial results from the trial by the end of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments